Dr. Li Zhuang 庄莉
Chief Physician
Department of Palliative Medicine, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical comprehensive treatment for solid tumors, including lung cancer, liver cancer, gastric cancer, and lymphoma.
Dr. Li Zhuang is a Chief Physician and Master's supervisor at Yunnan Cancer Hospital. Dr. Zhuang serves as Director of the Rehabilitation and Palliative Medicine Department and Head of the Yunnan Palliative Research Center.
Professional roles
- Standing Committee Member, Chinese Medical Association
- Chair, Cancer Rehabilitation and Palliative Care Committee, Yunnan Anti-Cancer Association
- Vice Chair, Microwave Tumor Hyperthermia Expert Committee, China Anti-Cancer Association Hyperthermia Professional Committee
- Standing Committee Member, Cancer Rehabilitation and Palliative Care Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhuang Li). Papers usually list the name as Li Zhuang or Zhuang L.
Selected publications
31 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Pain Res (Lausanne), 2026 (senior author): Case Report: Application of the 6D BTS digital assessment system in the comprehensive management of refractory cancer pain in a patient with gallbladder carcinoma. PubMed 42923792
- Front Oncol, 2026 (senior author): Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy. PubMed 42676823
- Front Oncol, 2026 (senior author): Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. PubMed 41717411
- Front Oncol, 2025 (senior author): SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. PubMed 40766331
- Medicine (Baltimore), 2024 (senior author): Development of a nomogram for predicting cancer pain in lung cancer patients: An observational study. PubMed 39612415
- J Transl Med, 2023 (senior author): HNRNPA2B1-mediated m(6)A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis. PubMed 37308993
- Front Genet, 2023 (senior author): Construction and validation of an angiogenesis-related lncRNA prognostic model in lung adenocarcinoma. PubMed 36999053
- Ann Palliat Med, 2022 (senior author): A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. PubMed 35365042
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion